Bamburg Wesley Shane 4

What Happened Wesley Shane Bamburg, Chief Operating Officer of Nutex Health (NUTX), was recorded as acquiring 2,411 derivative awards on March 11, 2026 at an effective price of $0.00. The filing shows the transaction as an exercise/conversion of a derivative (transaction code M), and footnotes clarify these are restricted stock units (RSUs) granted as compensation rather than an open-market purchase or sale. No cash changed hands at acquisition; this is an equity award that vests over time.

Key Details

• Transaction date and price: March 11, 2026 — 2,411 RSUs acquired at $0.00 (derivative/RSU grant).
• Vesting: Footnote states the 2,411 RSUs vest in three equal installments on March 1, 2027; March 1, 2028; and March 1, 2029.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on March 24, 2026 for a March 11 transaction — this appears to be a late filing (Form 4s are generally required within 2 business days).
• Notes: F1 clarifies each RSU is a contingent right to one common share upon vesting; F2 documents the grant date and vesting schedule.

Context RSUs are a common form of executive compensation and represent a promise to deliver shares if vesting conditions are met; they do not represent immediate sale or purchase of open-market stock. Because this is an award rather than a purchase, it is typically viewed as routine compensation rather than a direct bullish or bearish market signal. The late filing may be of administrative interest to investors monitoring insider reporting compliance.